– USA, CA – ExThera Medical Corporation announced today that it has appointed John Feik to its board of directors, effective immediately.
Mr. Feik has worked in the pharmaceutical industry for the past 35 years. His most recent position was President and Chief Operating Officer of DFB Pharmaceuticals, Inc., San Antonio, Texas. In addition to his previous posts, he has been working in other sectors of the biotech market as an investor, involved with companies such as HealthPoint Biotherapeutics, Phyton Biotech, and StemBioSys, Inc.
As a philanthropist, Mr. Feik has served on the private boards of the Texas BioMedical Research Institute, BioBridge Global, and the Texas Research & Technology Foundation. A major philanthropic project for him and his wife, Rita, has been the newly-created Feik School of Pharmacy at the University of the Incarnate Word.
Independent laboratories have demonstrated that ExThera Medical’s Seraph® Microbind® Affinity Blood Filter (Seraph) can remove an extremely broad range of bacteria, viruses, fungi and toxins from whole blood. No other therapy—drug or medical device—is designed to be as effective as Seraph in removing so many different pathogens and toxins from the blood of bacteremic and viremic patients.” The company introduced its Seraph® device to clinicians earlier this year at the annual congress of the Society for Critical Care Medicine.
“We are extremely pleased to welcome John to our leadership team,” said Robert S. (“Bob”) Ward, CEO of ExThera Medical. “His extensive experience in the pharmaceutical industry will help us move more quickly toward regulatory approval and subsequent commercialization of our breakthrough hemoperfusion device.”
Mr. Feik stated, “As an executive who has built international life science companies in the past, I am especially excited to join in ExThera’s mission to bring this new, highly innovative therapeutic device to the clinical community. With the increasing incidence of bloodstream infections caused by drug-resistant bacteria, there is little doubt that ExThera will play a role in setting new standards of care in the near future.”
About ExThera Medical
Privately held ExThera Medical, based in Berkeley, Calif., is targeting the clinical treatment of blood-borne diseases including bacteremia, as well as the removal of harmful substances present in banked human blood. While medical treatments of bacteremia, e.g., caused by S. aureus or MRSA (Methicillin-Resistant S. Aureus) usually rely on antibiotics, ExThera Medical’s Seraph® device capitalizes on the affinity of bacteria to attach to immobilized heparin within the device—a natural anticoagulant, that has many other biological attributes. Seraph® is designed to be a biomimetic adjunct to antibiotic therapy that reduces bacterial load and the duration of bacteremia, thereby potentially preventing complications such as endocarditis, osteomyelitis, and a systemic inflammatory response.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
